螺旋断层放疗实施立体定向体部放疗治疗早期肺癌有无病理证实的长期结局比较
本研究比较2011年6月至2016年12月期间接受螺旋断层放疗实施立体定向体部放疗的119例早期肺癌患者,其中55例为临床诊断、64例为病理诊断。中位随访69个月,两组5年局部控制、无进展生存、肿瘤特异生存和总生存均无显著差异,复发模式和毒性相似。作者认为,在多学科框架下,对高度怀疑恶性但无法或拒绝获取病理诊断的孤立性肺结节患者,经验性立体定向体部放疗似乎是安全有效的治疗选择。
要点
- 临床诊断组与病理诊断组5年局部控制分别为87%和83%(p=0.58),无显著差异。
- 两组5年无进展生存48%对45%(p=0.82)、肿瘤特异生存87%对84%(p=0.65)、总生存60%对63%(p=0.79)。
- 临床诊断组年龄显著高于病理诊断组(p=0.002),复发模式和毒性相似。
核心结论
- 在多学科框架下,对高度怀疑恶性但无法或拒绝获取明确病理诊断的孤立性肺结节患者,经验性立体定向体部放疗似乎是安全有效的治疗选择。
研究设计与样本
- 2011年6月至2016年12月期间,119例早期肺癌患者接受螺旋断层放疗实施立体定向体部放疗,其中55例为临床诊断、64例为病理诊断,比较两组的生存结局。
主要发现
- 全组中位随访69个月;临床诊断组年龄显著大于病理诊断组(p=0.002)。
- 临床诊断组与病理诊断组5年局部控制分别为87%和83%(p=0.58),无显著差异。
- 临床诊断组与病理诊断组5年无进展生存分别为48%和45%(p=0.82),无显著差异。
- 临床诊断组与病理诊断组5年肿瘤特异生存分别为87%和84%(p=0.65),无显著差异。
- 临床诊断组与病理诊断组5年总生存分别为60%和63%(p=0.79),无显著差异;复发模式和毒性也相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic body radio therapy (SBRT) has emerged as a standard treatment option for nonsurgical candidates with early-stage non-small cell lung cancer (NSCLC). Pathological proof is sometimes difficult to obtain in patients with solitary pulmonary nodules (SPNs). We aimed to compare the clinical outcomes of stereotactic body radiotherapy via helical tomotherapy (HT-SBRT) for early-stage lung cancer patients with or without a pathological diagnosis. METHODS: Between June 2011 and December 2016, we treated 119 lung cancer patients with HT-SBRT, including 55 with a clinical diagnosis and 64 with a pathological diagnosis. Survival outcomes, including local control (LC), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared between two cohorts with and without a pathological diagnosis. RESULTS: The median follow-up for the whole group was 69 months. Patients with a clinical diagnosis were significantly older (p = 0.002). No significant differences were observed between the clinical and pathological diagnosis cohorts in terms of the long-term outcome, with 5-year LC, PFS, CSS, and OS of 87% versus 83% (p = 0.58), 48% versus 45% (p = 0.82), 87% versus 84% (p = 0.65), and 60% versus 63% (p = 0.79), respectively. Recurrence patterns and toxicity were also similar. CONCLUSIONS: Empiric SBRT appears to be a safe and effective treatment option in a multidisciplinary setting when patients with SPNs highly suggestive of malignancy are unable/refuse to obtain a definitive pathological diagnosis.
引用
- Fan S, Zhang Q, Chen J, et al. Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof. Radiat Oncol. 2023. PMID: 36890550. doi:10.1186/s13014-023-02229-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。